Telix Pharmaceuticals (CHIA:TLX) - Hisse Senedi Fiyatı, Haberler ve Analizler

TLX Stoklara Genel Bakış

TLX temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	6/6
Geçmiş Performans	3/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 48% daha düşük bir oranda işlem görüyor

Kazançların yılda 38.32% oranında artması öngörülüyor

Bu yıl karlı hale geldi

Risk Analizi

Hissedarlar geçen yıl sulandırıldı

Telix Pharmaceuticals Limited Rakipler

Race Oncology

ASX:RAC

AU$231.8m

Clinuvel Pharmaceuticals

ASX:CUV

AU$669.3m

CSL

ASX:CSL

AU$132.8b

Orthocell

ASX:OCC

AU$149.4m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Telix Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$23.02
52 Haftanın En Yüksek Seviyesi	AU$23.99
52 Haftanın En Düşük Seviyesi	AU$9.07
Beta	2.38
11 Aylık Değişim	7.02%
3 Aylık Değişim	16.44%
1 Yıllık Değişim	151.58%
33 Yıllık Değişim	216.64%
5 Yıllık Değişim	1,226.80%
Halka arzdan bu yana değişim	3,658.37%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	TLX	AU Biotechs	AU Pazar
7D	0.09%	-5.0%	1.4%
1Y	151.6%	9.8%	17.7%

Getiri vs. Endüstri: TLX geçen yıl % 9.8 oranında getiri sağlayan Australian Biotechs sektörünü aştı.

Getiri vs Piyasa: TLX geçen yıl % 17.7 oranında getiri sağlayan Australian Piyasasını aştı.

Fiyat Oynaklığı

Is TLX's price volatile compared to industry and market?
TLX volatility
TLX Average Weekly Movement	5.6%
Biotechs Industry Average Movement	10.0%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

İstikrarlı Hisse Senedi Fiyatı: TLX son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: TLX 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2015	423	Chris Behrenbruch	telixpharma.com

Ticari aşamada bir biyofarmasötik şirketi olan Telix Pharmaceuticals Limited, Avustralya, Belçika, Japonya, İsviçre ve Amerika Birleşik Devletleri'nde kanser ve nadir hastalıklar için terapötik ve tanısal radyofarmasötiklerin geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Şirket, prostat kanseri tedavisi için Illuccix ve görüntüleme osteomiyelit tedavisi için TLX66-CDx ürünlerini sunmaktadır. Ürün adayları arasında prostat kanseri tedavisi için bir radyo antikor-ilaç konjugatı olan TLX591; renal (böbrek) kanserinin tedavisi ve teşhisi için TLX250-CDx; beyin (glioma) kanseri için TLX101-CDx; kemik iliği koşullandırmasını tedavi etmek için TLX66-CDx; yumuşak doku sarkomunun tedavisi ve teşhisi için TLX300-CDx ve berrak hücreli renal hücreli karsinom tedavisi için TLX250 bulunmaktadır.

Telix Pharmaceuticals Limited Temel Bilgiler Özeti

Telix Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
TLX temel i̇stati̇sti̇kler
Piyasa değeri	AU$7.68b
Kazançlar(TTM)	AU$49.19m
Gelir(TTM)	AU$645.68m

156.2x

F/K Oranı

11.9x

P/S Oranı

TLX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
TLX gelir tablosu (TTM)
Gelir	AU$645.68m
Gelir Maliyeti	AU$240.33m
Brüt Kâr	AU$405.35m
Diğer Giderler	AU$356.16m
Kazançlar	AU$49.19m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.15
Brüt Marj	62.78%
Net Kâr Marjı	7.62%
Borç/Özkaynak Oranı	2.9%

TLX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

TLX Stoklara Genel Bakış

Ödüller

Risk Analizi

Telix Pharmaceuticals Limited Rakipler

ASX:RAC

AU$231.8m

ASX:CUV

AU$669.3m

ASX:CSL

AU$132.8b

ASX:OCC

AU$149.4m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors

Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy

Health Canada Approves Label Expansion for Telix Pharmaceuticals Limited's Illuccix to Include Patient Selection for PSMA-Targeted Therapy

Telix Pharmaceuticals Initiates Phase II Trial for Tlx250-Cdx in Recurrent Clear Cell Renal Cell Carcinoma

Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire RLS (USA) Inc. from Rls Group Ltd for $250 million.

Recent updates

Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors

Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy

Health Canada Approves Label Expansion for Telix Pharmaceuticals Limited's Illuccix to Include Patient Selection for PSMA-Targeted Therapy

Telix Pharmaceuticals Initiates Phase II Trial for Tlx250-Cdx in Recurrent Clear Cell Renal Cell Carcinoma

Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire RLS (USA) Inc. from Rls Group Ltd for $250 million.

Telix Submits NDA for TLX101-Cdx (Pixclara®) Brain Cancer Imaging Agent

Second quarter 2024 earnings released: EPS: AU$0.035 (vs AU$0.018 loss in 2Q 2023)

Telix Pharmaceuticals Limited Announces Expanded Access Program Opens in the U.S. for Tlx101-Cdx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent

Telix Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024

Telix Pharmaceuticals Limited has withdrawn its Follow-on Equity Offering in the amount of $201.79 million.

First quarter 2024 earnings released: EPS: AU$0.056 (vs AU$0.027 loss in 1Q 2023)

Telix Pharmaceuticals Limited Submits NDA for New Prostate Cancer Imaging Agent

Telix Pharmaceuticals Limited has filed an IPO in the amount of $100 million.

Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024

Now 20% overvalued after recent price rise

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of ARTMS, INC.

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.

Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent

Telix Pharmaceuticals Limited (ASX:TLX) signed an agreement to acquire ARTMS, INC. for approximately $84 million.

Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million.

Full year 2023 earnings released: EPS: AU$0.016 (vs AU$0.34 loss in FY 2022)

Telix Pharmaceuticals Limited, Annual General Meeting, May 22, 2024

Telix Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 22, 2024

Forecast breakeven date pushed back to 2024

Telix Pharmaceuticals Limited Announces Executive Changes

Telix Pharmaceuticals Limited Submits Biologics License Application for TLX250-CDx (Zircaix) for Imaging of Kidney Cancer

Telix Pharmaceuticals Limited Announces First Patient Dosed in European Named Patient ( Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

Telix Pharmaceuticals Limited (ASX:TLX) signed a non-binding term sheet to acquire QSAM Biosciences, Inc. (OTCPK:QSAM) for $33.1 million.

Telix Pharmaceuticals Limited (ASX:TLX) acquired Lightpoint Surgical Limited from Lightpoint Medical, Ltd AUD 51 million.

Telix Pharmaceuticals Limited Announces Positive Preliminary Results from the Phase I ProstACT SELECT Study of Its rADC Therapy Candidate TLX591

Telix Pharmaceuticals Limited Announces First Patients Dosed in Chinese Imaging Studies

Telix Pharmaceuticals Limited to Report Q3, 2023 Results on Oct 18, 2023

New minor risk - Shareholder dilution

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Forecast breakeven date moved forward to 2023

Telix Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 23, 2023

Forecast to breakeven in 2023

Telix Pharmaceuticals Limited to Report Q2, 2023 Results on Jul 19, 2023

Telix Pharmaceuticals Limited to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI

Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire Lightpoint Surgical Limited from Lightpoint Medical, Ltd for AUD 51 million.

Telix Pharmaceuticals Limited Announces First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion

Insider recently bought AU$343k worth of stock

Full year 2022 earnings released: AU$0.34 loss per share (vs AU$0.28 loss in FY 2021)

Telix Pharmaceuticals Limited Announces Detailed Positive Results from its Completed Pivotal Phase III ZIRCON Trial

Forecast breakeven date pushed back to 2024

Telix Pharmaceuticals Limited to Report Q4, 2022 Results on Jan 18, 2023

Telix Pharmaceuticals Limited Announces ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances

Insider recently bought AU$73k worth of stock

Telix Pharmaceuticals Limited Announces Leadership Changes

Telix Pharmaceuticals Limited Announces Illuccix Kit for the Preparation of Gallium Ga 68 Gozetotide Injection

Telix Pharmaceuticals Limited Announces That First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy

Insufficient new directors

Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire Optimal Tracers from Northern California PET Imaging Center.

Telix Pharmaceuticals Limited Announces Positive Topline Results from Overseas Phase III Clinical Trial Has Met Clinical Endpoints

Telix Pharmaceuticals Limited Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study